captan
agrimart industries pty ltd - captan - unknown - captan carboximide active 0.0 - active constituent
kendon captan wg fungicide
kendon chemical & mnfg co. pty. limited - captan - water dispersible granule - captan carboximide active 800.0 g/kg - fungicide - apple | grape | ornamental seedling | pear | rose | stone fruit (see label for exceptions) | strawberry | tobacco seedling | tur - black spot - colletotrichum acutatum | black spot on apples | black spot on grapes - elsinoe ampelina | black spot on pears | black spot on rose | blossom blight - sclerotinia laxa | brown patch - rhizoctonia solani | brown rot | damping off - phytophthora spp. | downy mildew on grape | gloeosporium fruit rot | grey mould - botrytis cinerea | leaf blight | phytophthora fruit rot - phtophthora nic | scorch | anthracnose | apple scab | botrytis blight | botrytis rot | bunch rot
captan
adama australia pty limited - captan - unknown - captan carboximide active 0.0 - active constituent
captan manufacturing concentrate
arysta lifescience north america llc - captan - unknown - captan carboximide active 0.0 - active constituent
captan manufacturing concentrate
nufarm australia limited - captan - unknown - captan carboximide active 0.0 - active constituent
captan
adama australia pty limited - captan - unknown - captan carboximide active 0.0 - active constituent
agpro captan 900 wdg
agpro (nz) ltd - captan - captan 900 g/kg - fungicide
jynarque- tolvaptan kit jynarque- tolvaptan tablet
otsuka america pharmaceutical, inc. - tolvaptan (unii: 21g72t1950) (tolvaptan - unii:21g72t1950) - jynarque is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (adpkd). jynarque is contraindicated in patients: - with a history, signs or symptoms of significant liver impairment or injury. this contraindication does not apply to uncomplicated polycystic liver disease [see warnings and precautions (5.1)] - taking strong cyp 3a inhibitors - with uncorrected abnormal blood sodium concentrations [see warnings and precautions (5.3)] - unable to sense or respond to thirst [see warnings and precautions (5.3)] - hypovolemia [see warnings and precautions (5.3)] - hypersensitivity (e.g., anaphylaxis, rash) to tolvaptan or any component of the product [see adverse reactions (6)] - uncorrected urinary outflow obstruction - anuria risk summary available data with jynarque use in pregnant women are insufficient to determine if there is a drug associated risk of adverse developmental outcomes. in embryo-fetal development studies, pregnant rats a
captan
krishi rasayan exports pvt. ltd - captan - unknown - captan carboximide active 0.0 - active constituent
captan
aimco kr australia pty ltd - captan - unknown - captan carboximide active 0.0 - active constituent